36 results about "Isocitrate Dehydrogenase (NAD+)" patented technology

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:where A, B, W1, W2, W3, and R1-R8 are described herein.

The invention discloses a double-aryl maleimide compound, pharmaceutically acceptable salt thereof, a method for preparing the double-aryl maleimide compound and the pharmaceutically acceptable salt and application of the double-aryl maleimide compound and the pharmaceutically acceptable salt. The double-aryl maleimide compound and the pharmaceutically acceptable salt can be particularly used as isocitrate dehydrogenase 1 (IDH1) mutant inhibitors and can be applied to treating malignant tumor such as glioma and acute myeloid leukemia. The double-aryl maleimide compound, the pharmaceutically acceptable salt, the method and the application have the advantages that the double-aryl maleimide compound has efficiently selective IDH1 mutant inhibitory activity, and accordingly the double-aryl maleimide compound and the pharmaceutically acceptable salt can be used for treating the IDH1 mutant mediated malignant tumor such as the glioma and the acute myeloid leukemia; the double-aryl maleimide compound, the pharmaceutically acceptable salt and the method are reasonable in design, and the method is simple and practical.

The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:

The present invention relates to a cytosolic isocitrate dehydrogenase, its gene, and its use in the treatment of obesity, hyperlipidemia, and fatty liver. The expression of the IDPc gene and the concomitant increase in IDPc level bring about an increase in the cellular level of NADPH, which causes the lipid deposition in adipocytes, leading to obesity and fatty liver. A decrease in the cellular level of NADPH, resulting from the suppression of the gene expression of IDPc, has the effect of inhibiting the lipid deposition in adipocytes. Further, by taking advantage of the suppressive or inhibitory effects of isocitrate dehydrogenase inhibitors, pharmaceutically effective materials for the prophylaxis and treatment of obesity, hyperlipidemia and fatty liver can be developed.

The invention relates to a construction method of escherichia-coli gene engineering bacterium generating L-carnitine and an application. The gene engineering bacterium is characterized by converting encoded crotonbetaine into three key genes of the L-carnitine, namely caiB, caiC and caiD, transferring the three key genes, a transporter encoding gene caiT and a positive regulator caiF into escherichia coli for overexpression, controlling by an anaerobic promoter or adopting IPTG to induce expression of related genes for synthesis of the L-carnitine, and simultaneously deleting aceK gene for encoding isocitrate dehydrogenase phosphatase / kinase of the escherichia coli. After the gene enginering bacterium is cultured by production enzyme, and thalli are collected as a whole-cell enzyme source; the crotonbetaine is directly converted to generate the L-carnitine, after conversion, the yield of the L-carnitine can reach more than 30g / L, the molar conversion rate is 42% at highest, the yield and the conversion rate are increased by more than 60 times than those of wild plants, and the construction method reaches the leading level of biological-process preparation reported domestically. The gene engineering bacterium has a high conversion rate for substrate, the enzyme-reaction process is simple, the cost of production materials is low, the resource is saved and no pollution is caused.

The present invention finds that the compound of general formula (I) with an isoxazole skeleton has excellent inhibitory activity on mutant IDH1 protein, can inhibit the production of 2-HG through the protein, and can effectively inhibit various tumors expressing the protein proliferation.

The invention relates to a method for measuring ammonia (ammonia ion) content through an enzymatic colorimetric method and an enzyme coupling reaction technique, and the composition and the constituents of a reagent. The measuring technical principle of the method is fulfilled through the serial catalytic reactions of ammonia kinase, pyruvate carboxylase, and isocitrate dehydrogenase. The invention further relates to an ammonia (ammonia ion) diagnosing / measuring kit. The method provided by the invention has the advantages of high sensitivity and small error, so that the method and the kit provided by the invention can be widely applied to clinical medicine / food inspections.

The present invention provides a method for designing and constructing high-efficiency use of electrical energy to fix CO by using synthetic biotechnology. 2 And the method and application of engineering bacteria for synthesizing isopropanol. The method of designing and constructing engineering bacteria is to be able to utilize electric energy and CO. 2 electroactive microorganisms Geobacter sulfurreducens ACL is the chassis. In the chassis strain, isocitrate dehydrogenase and isopropanol synthesis pathway-related enzymes are efficiently expressed by plasmids. It has been verified by experiments that the strain constructed by this method can efficiently utilize electricity and CO. 2 Synthesis of isopropanol.

The invention relates to an ammonia (ammonium ion) content determination method through utilizing enzymatic colorimetry and an enzyme-linked immunosorbant assay technology, and the composition and components of a reagent for the determination. According to the determination technology principle, the determination is completed according to a series of catalytic reactions of an ammonia kinase, a propionyl CoA carboxylase and an isocitrate dehydrogenase. The invention also relates to an ammonia (ammonium ion) diagnosis / determination kit. The determination method of the invention has the advantages of high sensitivity and small error, so the determination method and the kit of the invention can be widely applied to clinical medicine / food examination.

Disclosed are compounds that inhibit the conversion of alpha-KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof, and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat IDH related diseases, including cancers.

The invention relates to a genetic biochemical site marker for cerebral ischemia inbred line meriones unguiculatus and application of the biochemical site marker. The genetic biochemical site marker for the cerebral ischemia inbred line meriones is selected from at least one of glucose-6-phosphate dehydrogenase-1, esterase-3, carbonic anhydrase-2, alkaline phosphatase-1, isocitrate dehydrogenase-1, malic enzyme-1, glucose phosphate translocase-1, renal catalase-2, peptidase-3, glucose phosphate isomerase-1, hemoglobin-beta chain, transferring, esterase-1, esterase-10, glycerol phosphate dehydrogenase-1, beta-glucuronidase-1, esterase-2, lactic dehydrogenase regulator-1, serum protein-1, amylase-1, esterase-6, esterase-8, esterase-9, esterase-4, catalase-1 and esterase-12.

The invention is applicable to the technical field of kit preparation, and provides a total bilirubin determination kit preparation method, which comprises the steps of: A, preparing a reagent 1, the reagent 1 comprising a citric acid buffer solution, a surfactant and triton, the components of the citric acid buffer solution comprising isocitrate dehydrogenase, lactic dehydrogenase, a stabilizer and a coenzyme; B, preparing a single reagent, wherein the single reagent comprises disodium hydrogen phosphate, monopotassium phosphate, sodium vanadate and disodium ethylene diamine tetraacetate; C, uniformly stirring and mixing the citric acid buffer solution and the single reagent, keeping the temperature at 37 DEG C for 3-10 minutes, adding the enzyme reagent, and uniformly mixing to obtain a reaction solution; and D, pouring the reaction liquid into a kit, wherein a substrate reagent is carried in the kit, and the substrate reagent comprises an oxidase substrate and a substrate buffer solution. Therefore, the influence of lipid turbidity on detection can be eliminated, so that the detection accuracy is improved.